Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25686955 | 1.00 | CFTR (0.34) | CFTRHTR2CSLC34A1CNR2HPGDS | |
| SCHEMBL23958632 | 1.00 | CFTR (0.34) | CFTRHTR2CSLC34A1CNR2HPGDS | |
| SCHEMBL25686991 | 0.91 | PRKACA (0.33) | CNR1 | |
| SCHEMBL30007237 | 0.91 | CFTR (0.33) | CFTRHTR2CSLC34A1CNR2HPGDS | |
| SCHEMBL23958854 | 0.91 | PRKACA (0.33) | CNR1 | |
| SCHEMBL23958975 | 0.90 | DGAT1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL23958767 | 0.90 | DGAT1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL23958735 | 0.90 | TRPV1 (0.33) | CFTRDPP4 | |
| SCHEMBL23958657 | 0.90 | TRPV1 (0.33) | CFTRDPP4 | |
| SCHEMBL26727263 | 0.90 | CFTR (0.33) | CFTRSLC34A1CNR2HPGDSCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023211997-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885HTR2C 1060/4885SLC34A1 2493/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | CFTR 126/4885HTR2C 3628/4885SLC34A1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.